Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme

The companies will identify a papain-like protease candidate to progress into the clinic

- PMLiVE

Pfizer/BioNTech submit FDA application for BA.4/BA.5 COVID-19 vaccine in children under five

The vaccine is already authorised as a booster for ages five years and older in the US and EU

- PMLiVE

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis

- PMLiVE

Pfizer and Valneva report six-month antibody persistence data for Lyme disease vaccine

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

NICE publishes draft guidance recommending three COVID-19 treatments

Five treatments have not been recommended for use, with the organisation citing cost-effectiveness concerns

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation for children five to 11 years

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma

The treatment showed a significant improvement in overall survival versus placebo

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

- PMLiVE

Pfizer and BioNTech dose first patient in COVID-19/flu combination vaccine study

The vaccine aims to protect individuals against two severe respiratory viral diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links